MetaCap

Enanta Pharmaceuticals (ENTA) vs Keros Therapeutics (KROS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Keros Therapeutics (KROS) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, losing 36.3% versus a loss of 40.1%. Over five years, KROS leads with a -80.2% price change compared with -91.7% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $217.4 million), about 1.0 times the size.

Keros Therapeutics converts more of its revenue into profit, with a net margin of 35.7% versus -108.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENTA-40.14%KROS-36.29%
+36%-7%-51%
Nov 21, 20251 yearNov 20, 2026
ENTA-89.88%KROS-81.48%
+28%-36%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENTA versus KROS key metrics
MetricENTAKROS
Share price$7.62$11.08
Market cap$222.19M$217.44M
1-day change-4.51%-2.72%
YTD return-51.68%-45.58%
1-year return-40.14%-36.29%
5-year return-91.71%-80.25%
EPS (TTM)$-2.35$-2.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.00M$243.86M
Revenue growth (YoY)-3.56%—
Net income (latest FY)$-68.25M$87.01M
Operating margin-99.01%27.71%
Net margin-108.33%35.68%
52-week high$17.15$22.55
52-week low$7.56$8.98
Distance from 52-week high-55.57%-50.86%
Analyst consensusstrong_buybuy
Avg. price target upside+186.48%+78.97%
Average volume287.81K196.50K
Shares outstanding29.16M19.62M
Employees12087
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Keros Therapeutics is more profitable, keeping 35.7 cents of every revenue dollar as net income versus -108.3 cents for Enanta Pharmaceuticals.

About Enanta Pharmaceuticals

ENTA stock →

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

About Keros Therapeutics

KROS stock →

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

ENTA vs KROS FAQ

Which is bigger, Enanta Pharmaceuticals or Keros Therapeutics?

Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $217.44M for Keros Therapeutics (KROS).

Which stock has performed better over the past year, ENTA or KROS?

KROS returned -36.29% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.

Are Enanta Pharmaceuticals and Keros Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons